Apogee Therapeutics (APGE) EBIT (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of EBIT data on file, last reported at -$82.8 million in Q1 2026.

• EBIT for Q1 2026 came in at -$82.8 million, down 31.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$73.3 million (down 16.12% YoY), and the FY2025 annual result was -$53.7 million, down 40.32% from the prior year.
• EBIT slipped to -$82.8 million in Q1 2026 per APGE's latest filing, from $153.9 million in the prior quarter.
• Over five years, EBIT peaked at $153.9 million in Q4 2025 and troughed at -$82.8 million in Q1 2026.
• A 5-year average of -$13.7 million and a median of -$21.6 million in 2023 frame the typical range for EBIT.
• On a YoY basis, EBIT climbed as much as 371.02% in 2023 and fell as far as 939.92% in 2023.
• A 5-year view of EBIT shows it stood at -$14.1 million in 2022, then jumped by 371.02% to $38.2 million in 2023, then soared by 168.88% to $102.7 million in 2024, then surged by 49.76% to $153.9 million in 2025, then plunged by 153.79% to -$82.8 million in 2026.
• Business Quant data shows APGE's EBIT at -$82.8 million in Q1 2026, $153.9 million in Q4 2025, and -$71.3 million in Q3 2025.